Taiwan · Delayed Price · Currency is TWD ACRO Biomedical Statistics
Total Valuation
ACRO Biomedical has a market cap or net worth of TWD 13.32 billion. The enterprise value is 12.43 billion.
| Market Cap | 13.32B |
| Enterprise Value | 12.43B |
Important Dates
The next estimated earnings date is Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRO Biomedical has 71.22 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 71.22M |
| Shares Outstanding | 71.22M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 10.05% |
| Owned by Institutions (%) | n/a |
| Float | 56.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 252.43 |
| PB Ratio | 12.50 |
| P/TBV Ratio | 12.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 235.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 62.28, with a Debt / Equity ratio of 0.03.
| Current Ratio | 62.28 |
| Quick Ratio | 60.48 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.41 |
| Interest Coverage | -314.60 |
Financial Efficiency
Return on equity (ROE) is -9.57% and return on invested capital (ROIC) is -6.94%.
| Return on Equity (ROE) | -9.57% |
| Return on Assets (ROA) | -6.84% |
| Return on Invested Capital (ROIC) | -6.94% |
| Return on Capital Employed (ROCE) | -8.59% |
| Weighted Average Cost of Capital (WACC) | 5.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +108.02% in the last 52 weeks. The beta is 0.22, so ACRO Biomedical's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +108.02% |
| 50-Day Moving Average | 177.54 |
| 200-Day Moving Average | 93.90 |
| Relative Strength Index (RSI) | 44.03 |
| Average Volume (20 Days) | 1,034,030 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ACRO Biomedical had revenue of TWD 52.76 million and -78.79 million in losses. Loss per share was -1.18.
| Revenue | 52.76M |
| Gross Profit | 33.85M |
| Operating Income | -94.07M |
| Pretax Income | -78.79M |
| Net Income | -78.79M |
| EBITDA | -84.05M |
| EBIT | -94.07M |
| Loss Per Share | -1.18 |
Balance Sheet
The company has 916.68 million in cash and 33.63 million in debt, with a net cash position of 883.05 million or 12.40 per share.
| Cash & Cash Equivalents | 916.68M |
| Total Debt | 33.63M |
| Net Cash | 883.05M |
| Net Cash Per Share | 12.40 |
| Equity (Book Value) | 1.07B |
| Book Value Per Share | 14.84 |
| Working Capital | 943.36M |
Cash Flow
In the last 12 months, operating cash flow was -72.33 million and capital expenditures -9.22 million, giving a free cash flow of -81.55 million.
| Operating Cash Flow | -72.33M |
| Capital Expenditures | -9.22M |
| Depreciation & Amortization | 10.46M |
| Net Borrowing | -5.26M |
| Free Cash Flow | -81.55M |
| FCF Per Share | -1.15 |
Margins
Gross margin is 64.16%, with operating and profit margins of -178.30% and -149.34%.
| Gross Margin | 64.16% |
| Operating Margin | -178.30% |
| Pretax Margin | -149.34% |
| Profit Margin | -149.34% |
| EBITDA Margin | -159.32% |
| EBIT Margin | -178.30% |
| FCF Margin | n/a |
Dividends & Yields
ACRO Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
| Earnings Yield | -0.59% |
| FCF Yield | -0.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |